NEJM After randomization, 83 participants were assigned to receive the vaccine with adjuvant and 25 without adjuvant, and 23 participants were assigned to receive placebo. No serious adverse events … Read More
FDA briefing document on Moderna’s vaccine (pdf) … Throughout each stage of clinical testing, the Moderna vaccine proved to be safe and highly effective at preventing symptomatic COVID-19. In a study … Read More
JAMA The first 10 days after COVID-19 discharge appear to be a particularly risky period, according to a JAMA research letter. Researchers studied nearly 1800 COVID-19 patients who were discharged from … Read More
JAMA Question Is administration of systemic corticosteroids associated with reduced 28-day mortality in critically ill patients with coronavirus disease 2019 (COVID-19)? Findings In this prospective meta-analysis of 7 randomized trials that … Read More
NEJM, Dr. Harlan Krumholz, a co-author of this research letter, is also editor-in-chief of NEJM Journal Watch Cardiology. Among U.S. adults aged 25 to 44, there were 19% more deaths … Read More
Two randomized, controlled Phase 3 clinical trials have begun evaluating investigational monoclonal antibodies for their safety and efficacy in treating people hospitalized with moderate COVID-19. The trials are part … Read More
NEJM Group:Interview: Dr. Hanny Al-Samkari and his team examined whether giving therapeutic levels of anticoagulants to critically ill COVID-19 patients soon after admission to the ICU improved survival. He … Read More
The Lancet AstraZeneca vaccine: Findings from the interim analysis of the randomized trials of the AstraZeneca–University of Oxford vaccine have now been published in The Lancet. As previously reported, the adenovirus … Read More
NEJM, Eric J. Rubin, M.D., Ph.D., and Dan L. Longo, M.D. …….. Nevertheless, the trial results are impressive enough to hold up in any conceivable analysis. This is a triumph. … Read More
An FDA advisory committee voted on Thursday that the potential benefits of the Pfizer and BioNTech COVID-19 vaccine outweigh its risks for people ages 16 years and up. The … Read More
